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ABSTRACT
Background. The safety and practicality of nipple-sparing
mastectomy (NSM) are controversial.
Methods. Review of a large breast center’s experience
identified 99 women who underwent intended NSM with
subareolar biopsy and breast reconstruction for primary
breast cancer. Outcome was assessed by biopsy status,
postoperative nipple necrosis or removal, cancer recur-
rence, and cancer-specific death.
Results. NSM was attempted for invasive cancer (64
breasts, 24 with positive lymph nodes), noninvasive cancer
(35 breasts), and/or contralateral prophylaxis (50 breasts).
Twenty-two nipples (14%) were removed because of
positive subareolar biopsy results (frozen or permanent
section). Seven patients underwent a pre-NSM surgical
delay procedure because of increased risk for nipple
necrosis. Reconstruction used transverse rectus abdominis
myocutaneous flaps (56 breasts), latissimus flaps with
expander (35 breasts), or expander alone (58 breasts). Of
127 retained nipples, 8 (6%) became necrotic and 2 others
(2%) were removed at patient request. There was no nipple
necrosis when NSM was performed after a surgical delay
procedure. At a mean follow-up of 60.2 months, all 3
patients with recurrence had biopsy-proven subareolar
disease and had undergone nipple removal at original
mastectomy. There were no deaths.
Conclusions. Five-year recurrence rate is low when NSM
margins (frozen section and permanent) are negative.
Nipple necrosis can be minimized by incisions that maxi-
mize perfusion of surrounding skin and by avoiding long
flaps. A premastectomy surgical delay procedure improves
nipple survival in high-risk patients. NSM can be per-
formed safely with all types of breast reconstruction.
The observation that nipple-sparing mastectomy (NSM)
produces a cosmetic outcome superior to traditional non-
NSM can be traced in the modern era to a presentation by
Bromley Freeman in 1961. In his published report, Free-
man denied that his idea was original and cited a work from
1882 to support the contention that NSM is an inherently
less mutilating procedure than total mastectomy.1 NSM
achieves a better cosmetic outcome, but is it practical and
safe for the patient with breast cancer?
As early as 1984, Hinton et al. reported that NSM
achieved local recurrence and early survival rates equiva-
lent to those for modified radical mastectomy.2
Nonetheless, the oncologic community has remained
skeptical. Prominent surgeons have concluded that ‘‘nipple
sparing is not a reasonable option for mastectomy patients’’
and that ‘‘nipple areolar complex-sparing mastectomy may
carry an unacceptable high risk for local relapse and should
therefore not be advocated.’’3,4
The controversy over the safety of NSM may be similar
to the early controversy over the safety of breast-conserv-
ing procedures. Only a generation ago, the medical
community was divided over the question of whether
lumpectomy was as safe as mastectomy.5 In 2002, Vero-
nesi et al. and Fisher et al. reported 20-year follow-up data
for two independent multicenter trials comparing lumpec-
tomy, lumpectomy followed by radiation, and mastectomy
for breast cancers 4 cm and smaller.6,7 Although the trials
had different designs, both included two treatment arms in
which the nipple was preserved and one treatment arm in
which the nipple was removed. The fact that neither of
these prospective randomized trials identified a treatment-
related difference in long-term survival is evidence that
removal of the nipple is not associated with a survival
advantage in the initial treatment of breast cancer.8,9
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Starting in 1997, we offered NSM to selected cancer
patients who were considering mastectomy and breast
reconstruction. This study describes the oncologic criteria
for patient selection and reviews the surgical results of
NSM with respect to its practicality and safety.
METHODS
Candidates for NSM included women who had a diag-
nosis of invasive or noninvasive breast cancer and were
interested in the possibility of preserving the nipple-areolar
complex (NAC). Patients who had known or suspected
lymph node involvement were eligible. Those with tumor
involvement of the skin or nipple, invasive or noninvasive
tumors immediately under the NAC, or bloody nipple
discharge were not eligible. Also excluded were patients
who believed that the risk of NAC recurrence outweighed
the projected benefit of nipple preservation.
During the informed consent process, subjects were
fully informed that the long-term risks of NAC preserva-
tion were not certain but that the breast conservation
literature showed no survival advantage for immediate
removal of the nipple. All women were told that the NAC
would be preserved as a full-thickness flap, if possible, and
a subareolar biopsy specimen would be obtained at the time
of mastectomy. If frozen section analysis of the subareolar
tissue showed cancer, the nipple would be removed at the
time of mastectomy. If frozen section analysis showed no
cancer but permanent section showed disease postopera-
tively, subsequent removal of the nipple would be
performed. Nipples were not removed for borderline
pathologic changes such as atypia. All subjects were cau-
tioned that the blood supply to the nipple comes largely
from the breast tissue itself and an attempt at nipple pres-
ervation might result in postoperative necrosis of the
nipple, requiring subsequent removal even with no sign of
cancer. This study was approved by the Human Investi-
gations Institutional Review Board of the John Wayne
Cancer Institute.
During the 10-year study period, surgical incisions for
NSM evolved from periareolar to lateral or even infra-
mammary incisions to maximize perfusion of the nipple.
Mastectomies were performed as for any breast cancer; the
goal was to remove as much glandular tissue as possible
with flaps as thin as possible. Only a thin layer (\2 mm) of
subdermal tissue with only the subdermal plexus was
retained behind the NAC (Fig. 1). All fat and glandular
tissue was removed. Postoperative radiation or systemic
adjuvant treatments were determined by patient-related and
tumor-related characteristics and were not altered by the
presence or absence of the NAC.
As we gained more experience with NSM, we recom-
mended a premastectomy surgical delay procedure for
women with a perceived higher chance of postmastectomy
nipple necrosis.10 Indications for the delay procedure
included an active history of cigarette smoking, preexisting
surgical scars that would restrict blood supply to the nipple
after mastectomy (such as circumareolar scars; Fig. 2), or a
suprasternal notch-to-nipple distance of 28 cm or greater
(ptotic breast). During our outpatient delay procedure, the
skin of the anterior breast and the NAC is surgically sep-
arated from the blood supply of the underlying breast
tissue. This is performed in the same plane as a standard
mastectomy; the ducts going to the nipple are cut at the
thickness of the subdermal plane of mastectomy. The delay
procedure differs from a circumareolar biopsy because a
biopsy is not undertaken to separate the nipple from its
underlying vascular supply. The purpose of surgical sepa-
ration is to stimulate blood flow from the surrounding skin
to the NAC in the days before mastectomy and thereby
reduce the risk of nipple necrosis after mastectomy. The
delay procedure also allows premastectomy subareolar
biopsy, the results of which can aid plans for breast
reconstruction. NSM is performed 7 to 10 days after the
delay procedure.
Standard procedures were performed for breast recon-
struction. These included tissue expansion followed by
placement of a permanent silicone gel or saline-filled breast
FIG. 1 Nipple-sparing mastectomy performed using a lateral incision (a) that allows excellent exposure of the axillary tail. Patients without
long flaps or other risk factors tolerate thin subareolar flaps (b) as long as perfusion of the nipple-areolar complex approaches 360 degrees
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implant, latissimus dorsi myocutaneous flap reconstruction
with an expander/implant, or a microvascular muscle-
sparing free transverse rectus abdominis myocutaneous
(TRAM) flap.
Outcome measures included subareolar biopsy results
with intraoperative nipple removal, viability of the retained
nipple (postoperative nipple necrosis), postmastectomy
removal of the nipple, postoperative reconstructive flap
loss, infection requiring implant removal, local recurrence
of breast cancer, and death.
RESULTS
Between October 1997 and September 2008, a total of
149 NSM procedures were undertaken in 99 women who
had invasive ductal cancer (n = 48), invasive lobular
cancer (n = 16), or ductal carcinoma in situ (n = 35). Of
the 149 NSM procedures, 50 were contralateral mastecto-
mies performed at the patient’s request for risk reduction,
prophylaxis and/or symmetry of reconstruction.
The 99 subjects had a mean age of 51 years, mean
height of 65 inches, and mean weight of 142 pounds (mean
body mass index 23.3). Five subjects were smokers. Of 21
patients who had undergone prior lumpectomy for their
breast cancer, 19 also had received postoperative
radiotherapy.
Mean diameter of the primary breast tumor was 2.4 cm
(range 0.2–6.8 cm) for invasive cancer and 3.7 cm (range
0.5–10.0 cm) for ductal carcinoma in situ. Of the 64
patients with invasive cancer, 28 had American Joint
Committee on Cancer (AJCC) stage I disease, 26 had stage
II disease, and 10 had stage III disease; 24 (37%) of 64
patients had axillary lymph node metastasis, with 1 to 18
tumor-positive nodes.
At the time of mastectomy, frozen section analysis of
the subareolar biopsy specimen demonstrated invasive or
noninvasive cancer in 21 patients (15% of mastectomies,
21% of patients, and 21% of breasts with cancer); in each
case the NAC was sacrificed. (One of these patients, who
underwent successful NSM in the contralateral breast,
subsequently requested removal of her noninvolved nipple
for symmetry; this nonnecrotic nipple was removed several
months later.) One subareolar biopsy specimen was tumor-
free on frozen section analysis but positive for ductal car-
cinoma in situ on permanent section analysis. This was the
only false-negative frozen section examination (false-neg-
ative rate \1%). There were no false-positive frozen
section evaluations.
Of the 127 NACs that were preserved (because the
subareolar biopsy specimen was negative on frozen and
permanent sections), 8 (6.3%) developed ischemic necrosis
during the early postoperative period. Seven of these cases
were associated with ptotic breasts (nipple-to-notch dis-
tance of C28 cm), one of which had undergone prior
irradiation. In one case the breast was not ptotic (nipple-to-
notch distance of 22 cm) but the mastectomy incision was
along the superior margin of the NAC, allowing only 180
degrees of perfusion.
FIG. 2 Planned nipple-sparing mastectomy (NSM) after previous
mastopexy (circumareolar inverted T scar) (a). An outpatient surgical
delay procedure (b) performed 1 week before NSM ensured
maximum perfusion of the nipple-areolar complex (c). Final recon-
struction preserved all nipple tissue without loss of pigment (d)
Nipple-Sparing Mastectomy
A premastectomy surgical delay procedure was per-
formed in 7 of the 99 subjects, who were believed to be at
high risk for postoperative nipple necrosis because of
identified risk factors. None of these subjects developed
nipple necrosis after mastectomy.
Breast reconstruction consisted of 56 TRAM flaps
(37%) (54 muscle-sparing free flaps, 2 ‘‘delayed’’ uniped-
icle flaps), 35 latissimus dorsi myocutaneous flaps plus
tissue expanders (23%), and 58 expander/implant recon-
structions (40%). Of the 149 procedures, only one (1.7%)
required a return to the operating room, to repair vascular
occlusion of a microvascular free flap. All TRAM and
latissimus dorsi flaps survived. No tissue expanders or
implants were removed because of infection, skin necrosis,
or exposure.
Of the 99 subjects in this study, 16 (16%) underwent
subsequent radiotherapy to the reconstructed breast. At a
mean postoperative follow-up of 60.2 months (range
12–144 months), there have been no deaths and no nipple
recurrences. Mastectomy skin flap recurrence developed in
3 (14%) of 22 patients who underwent NAC removal
because of a positive subareolar biopsy specimen, as
compared with 0 recurrences in the 77 patients whose NAC
was preserved because the subareolar biopsy specimen was
negative (P = 0.0034). One of the 3 patients developed a
distant metastasis 5 years after her non-NSM. In all 3 of
these cases, the breast cancer recurred within 2 cm of the
original mastectomy incision. Because none of the recur-
rences occurred in patients whose NAC was retained,
surgical exposure in these cases was no different than in a
standard non-NSM.
DISCUSSION
Our 5-year mean follow-up data indicate a low rate of
breast cancer recurrence in the chest wall and NAC when
NSM is performed in patients with a tumor-free subareolar
biopsy specimen. Indeed, the only chest wall failures
observed in this study were in patients who had tumor
involvement of subareolar tissue and underwent nipple
removal at mastectomy. Radiotherapy may have been
important in achieving the low rate of local recurrence
because 16% of the patients in this study underwent post-
operative radiotherapy.
Hinton et al. compared patients treated with NSM and
implant reconstruction to a control group of patients treated
by simple mastectomy alone.2 At 56 months of follow-up,
they concluded that local ‘‘flap’’ recurrence and overall
survival rates were not greatly different between the two
treatment groups. Attention should be drawn to the
description of ‘‘subcutaneous’’ mastectomy specified by this
study: ‘‘The skin flaps…are of the same thickness as in
simple mastectomy…. Thus subcutaneous mastectomy dif-
fers from simple only in that no skin is excised and the nipple
remains intact.’’
Gerber et al. reported remarkably similar results in a
study of comparable size (61 patients vs. 70 patients
reported by Hinton et al.).2,11 Mean duration of follow-up
was 56 months in the Gerber study and 59 months in the
Hinton study; recurrence rates were 5.7% and 5.4%,
respectively. The percentage of patients with AJCC stage
II/III breast cancer was 81% in the Gerber study vs. 49% in
the Hinton study; corresponding rate of postoperative
radiotherapy was 27% vs. 0. Both groups concluded that
NSM did not result in marked differences in local recur-
rence or survival rates compared to nonrandomized
controls. In a recent update, Gerber et al. showed that with
a mean follow-up of 101 months, NSM seems safe.12
A comparison of various reports of NSM (Table 1)
demonstrates some unsurprising conclusions.2,11–18 First,
when NSM is performed in patients with stage II and stage
III disease, local recurrence increases; and second, when
patients with NSM are followed up for longer periods,
more local recurrences will be found. In a study reported
by Petit et al., intraoperative radiotherapy of the retained
NAC did not increase nipple necrosis.13 However, because
reported local recurrences rarely involve the retained nip-
ple, it is unclear whether intraoperative radiotherapy is
necessary.19 In patients with stage II and stage III disease,
consideration should be given to postoperative radiother-
apy, as for procedures that sacrifice the nipple.
Two lines of data converge to support the safety of
NSM. The assertion that initially aggressive surgery does
not improve breast cancer survival has been examined in
randomized, prospective studies with extended follow-
up.5–7 These breast conservation studies found no differ-
ence in survival if nipples were removed, as they were in
the mastectomy groups, or retained, as they were in the
lumpectomy groups. Smaller, nonrandomized studies
focused on NSM.14,16,17,20 These studies found low rates
(0% to 1.7%) of local recurrence within the NAC at
approximately 5 years of follow-up. Recurrence within the
skin flaps of patients with 5-year follow-up and comparable
disease ranges from 3% to 6%.2,11,12,16,17,20
Higher local failure is reported by Benediktsson and
Perbeck in their study from Sweden, which accumulated
216 patients treated from 1988 to 1994.18 Patients were
followed up for a minimum of 11.6 years, with a median
follow-up of 13 years. Local failure rate was 24% but there
were only 8 recurrences (4%) in the retained NAC. The
surgical procedure left a 5-mm layer of glandular tissue
beneath the NAC, which had a diameter of 2 cm. In their
study, 53% of patients had stage II or stage III breast
cancer and 40.3% had tumor-involved lymph nodes. The
rate of local failure was 8.5% in patients who received pre-
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or postoperative radiotherapy, as compared with 28.4% in
patients who did not receive radiotherapy. Locoregional
recurrence was independent of lymph node status or clin-
ical stage, and it compared favorably with the locoregional
recurrence rates reported in studies of modified radical
mastectomy from Scandinavia.21,22
NSM should be considered not only for patients with
breast cancers but also for women who seek risk reduction.
Subcutaneous mastectomies were performed at the Mayo
Clinic from 1960 to 1993. Of the more than 1,000 women
treated, 639 sought prophylactic mastectomy because of a
family history of breast cancer.23 The risk of developing
breast cancer was reduced 90% by this treatment. Such an
impressive study addresses the well-intentioned concerns
of earlier critics of this procedure.24,25 Of the 639 women,
only 7 developed breast cancer, and only 1 of the 7
developed breast cancer in a retained nipple. Blood sam-
ples were collected from 176 women thought to be at
highest risk and genetic tests were performed.26 BRCA
abnormality was identified in 26 women; at a mean follow-
up of 13.4 years none of these women had developed
breast cancer. These data argue strongly that NSM has a
role in the BRCA-positive patient. If the cosmetic outcome
of mastectomy were improved, more women might choose
to have such risk-reduction surgery. We are currently
investigating NSM for women with BRCA mutations.
Some patients would not seem to be good candidates for
nipple preservation because of well recognized risk factors
for flap necrosis: history of cigarette smoking, previous
incisions restricting postmastectomy blood supply to the
retained nipple (Fig. 2), or breast ptosis.27 Indeed, in our
early experience, nipple necrosis was observed most
commonly in patients with long, thin flaps as demonstrated
by a preoperative nipple to suprasternal notch distance of
greater than 28 cm. In 7 of the patients reported in this
study who had one or more of these risk factors, a prem-
astectomy surgical delay procedure was recommended
to maximize the chances of postmastectomy NAC sur-
vival. This procedure also had the benefit of allowing
premastectomy evaluation of subareolar tissue. A surgical
delay allows NSM to be offered to patients who might
seem to be poor candidates for nipple preservation because
of concerns about postoperative NAC perfusion.28
NSM results in a conflict for the oncoplastic team. A
good NSM must be performed using incisions that allow
adequate surgical exposure and are in the thin surgical
plane to avoid future occurrence or local recurrence of
breast cancer, but long thin mastectomy flaps are at higher
risk for postoperative necrosis. Our operation is similar to
that described by Hinton et al.2 It is a mastectomy differing
from a total mastectomy only in the amount of skin pre-
served and preservation of the NAC. Thick flaps and
retained breast tissue must be avoided. Subcutaneous
mastectomies often leave thick flaps with breast tissue
under the NAC and in the low axilla. This amount of
retained breast is likely to lead to recurrent or new cancer.
Attention to detail with careful construction of thin flaps,
‘‘complete’’ glandular resection, and cooperation and
planning between surgical oncologist and plastic surgeon
will result in a safe, aesthetic mastectomy.
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